Challenges for synthesising data in a network of registries for systemic psoriasis therapies

Dermatology

Volumn 224, Issue 3, 2012, Pages 236-243

  Ormerod, A D ^a   Augustin, M ^c   Baker, C ^d   Chosidow, O ^e   Cohen, A D ^f   Dam, T N ^g   Garcia Doval, I ^h   Lecluse, L L ⁱ   Schmitt Egenolf M , ^j   Spuls, P I ⁱ   Watson, K D ^b   Naldi, L ^k  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e HENRI MONDOR HOSPITAL   (France)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g ROSKILDE HOSPITAL   (Denmark)

^h Servicio de Dermatologia   (Spain)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j UMEÅ UNIVERSITY   (Sweden)

^k FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

more..

Author keywords

Biologics; Methodology; Psoriasis; Registry; Research network; Systemic therapy

Indexed keywords

ARTICLE; CODING; DATA ANALYSIS; DISEASE REGISTRY; FOLLOW UP; PRIORITY JOURNAL; PSORIASIS; VALIDATION PROCESS;

ADULT; BIOLOGICAL AGENTS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84863781790     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000338572     Document Type: Article

References (15)

1. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
2. Ashcroft DM, Li Wan Po A, Griffiths CE: Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000; 25: 1-10.
3. Schmitt-Egenolf M: Psoriasis therapy in real life: the need for registries. Dermatology 2006; 213: 327-330.
4. Patel RV, Clark LN, Lebwohl M, Weinberg JM: Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60: 1001-1017.
5. Kempen JH, Daniel E, Dunn JP, Foster CS, Gangaputra S, Hanish A, Helzlsouer KJ, Jabs DA, Kacmaz RO, Levy-Clarke GA, Liesegang TL, Newcomb CW, Nussenblatt RB, Pujari SS, Rosenbaum JT, Suhler EB, Thorne JE: Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009; 339: b2480.
6. Avorn J, Schneeweiss S: Immunosuppressants, mortality, and risk of cancer. BMJ 2009; 339:b1645.
7. Schmitt-Egenolf M: PsoReg-the Swedish registry for systemic psoriasis treatment. The registry's design and objectives. Dermatology 2007; 214: 112-117.
8. Stern RS, Liebman EJ, Vakeva L: Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA follow-up study. J Natl Cancer Inst 1998; 90: 1278-1284.
9. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V, Dubertret L: Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003; 120: 211-216.
10. Lecluse LL, Naldi L, Stern RS, Spuls PI: National registries of systemic treatment for psoriasis and the European 'Psonet' initiative. Dermatology 2009; 218: 347-356.
11. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD: British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
12. Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, Symmons DP: European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009; 68: 1240-1246.
13. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL: Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816-824.
14. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC: Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008; 300: 1887-1896.
15. Gladman DD, Ritchlin C, Helliwell PS: Psoriatic arthritis clinical registries and genomics. Ann Rheum Dis 2005; 64(suppl 2):ii103-ii105.